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Abstract Injecting drug use is a major driver of HIV
infections in Eastern Europe, the Commonwealth of Indepen-
dent States, North Africa, the Middle East, and many parts of
Asia and North America. We provide a global overview of the
epidemiology of HIV infection among drug users and present
current drug use trends that may constitute important epidemic
drivers. We describe trends in ethnic disparities among
injecting drug using (IDU) populations in the United States,
and comment upon how these trends may now be changing.
We present examples where HIV infection among non-IDUs
whouse cocaine,crack,andmethamphetamine byother routes
of administration is similar to that among IDUs, and discuss
potential mechanisms of HIV spread in this overlooked
population. Finally, we comment upon the potential implica-
tions of these observations for HIV interventions among IDU
and non-IDU populations, taking into account different
strategies that are needed in settings where HIV and/or
injectingdruguse hasbeenestablished,orthreatens toemerge.
Keywords HIV.AIDS.Injection drug use.Sub-Saharan
Africa.Needle exchange programs.Opioid substitution
treatment.Antiretroviral treatment.Prevention.
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Introduction
Drug dependence is a complex, chronic, relapsing condition
that is often accompanied by severe health, psychological,
economic, legal, and social consequences. Injecting drug
users (IDUs) are particularly vulnerable to HIV and other
blood-borne pathogens as a result of sharing contaminated
syringes and other injecting equipment (e.g., cookers, cotton,
and rinse water). Injecting drug use accounts for approxi-
mately 10% of HIV infections globally, but this proportion
rises to 30% outside of Africa [1•]. Injecting drug use is the
primary mode of HIV transmission in many countries
throughout Eastern Europe, the Commonwealth of Indepen-
dent States, North Africa, North America, the Middle East,
and many parts of Asia [1•]. However, unprotected sex is
also an important risk factor for HIV infection among IDUs,
especially among women and men having sex with men who
inject drugs (MSM-IDUs). In many parts of the world,
injecting drug use also indirectly accounts for a sizable
proportion of HIV cases spreading through sexual transmis-
sion from IDUs to non-injecting populations, and through
perinatal transmission to newborns. Below, we highlight
trends in the epidemiology of HIV infection among IDUs
and the increasing role of non-IDUs in various HIV
epidemics worldwide and in the United States.
Global Trends in the Epidemiology of HIV Infection
Among Drug Injectors
In2008, injecting drug use had been reportedin148 countries
and territories, but prevalence of injecting drug use was
available for fewer thanhalf(i.e.,61countries)[1•]. Based on
available data from these countries, country-level prevalence
of injecting drug use ranges widely from 0.02% in India and
Cambodia to Georgia with 4.19% and Azerbaijan with
5.21% [1•, 2]. Since injecting drug use is more common in
urban areas, country-level prevalence estimates can mask
considerable within-country heterogeneity.
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11.0–21.1 million) people might inject drugs worldwide
[1•]. China, the United States, the Russian Federation, and
Brazil are estimated to have the largest populations of IDUs
and together account for 45% of the total estimated
worldwide population of IDUs. However, data for the
extent of injecting drug use was absent for many countries
in Africa, the Middle East, and Latin America [1•].
Injecting drug use is responsible for an increasing
proportion of new HIV infections in many parts of the
world, including countries in Eastern Europe, South
America, and east and southeast Asia [1•]. HIV prevalence
among IDUs was reported as zero in only eight (5.4%) of
148 countries. In 2006, it was estimated that 3 million
(range 1–7 million) IDUs may be living with HIV
worldwide [1•]. In China, the United States, and Russia,
the three leading countries for injecting drug use, the HIV
prevalence among IDUs was 12%, 16%, and 37%,
respectively (Fig. 1)[ 1•]. High HIV prevalence estimates
were found in southeast Asia, Eastern Europe, and Latin
America, where the prevalence of HIV infection among
some subpopulations of people who inject drugs has been
reported to be over 40%. HIV prevalence among IDUs was
20–40% in five countries: Russia (37.2%), Spain (39.7%),
Cambodia (22.8%), Vietnam (33.9%), and Libya (22.0%).
HIV prevalence was over 40% in nine countries: Estonia
(72.1%), Ukraine (41.8%), Burma (42.6%), Indonesia
(42.5%), Thailand (42.5%), Nepal (41.4%), Argentina
(49.7%), Brazil (48.0%), and Kenya (42.9%) [1•].
A few regional injecting drug use associated HIV
epidemics deserve special mention. Ukraine is considered to
be the most HIV-affected country in Europe and Central Asia,
with an estimated 440,000 HIV-infected persons between the
ages of 15 and 49 years (1.63%) [3]. Ukraine’s HIVepidemic
began after the fall of the Iron Curtain, when changes in drug
trafficking patterns, a faltering economy, and high unemploy-
ment rates led large numbers of young people to turn to
injecting drugs, which were often home-made opiate prepa-
rations. In some cities, HIV prevalence among IDUs rose
fromnearlyzeroin1994tomorethan50%within2years,and
in the general population, HIV prevalence is 1–2%. It is
estimated that as many as 820,400 people will be infected by
2014 [4]. Nearby in the Russian Federation and in several
former Soviet republics, HIV prevalence and incidence is
also rising, such as in St. Petersburg, which has experienced
an explosive HIVepidemic in recent years [5]. While Russia
and the Ukraine have implemented needle exchange programs
(NEPs), they have been adamantly opposed to opioid
substitution therapies, especially in Russia where they remain
illegal.InUkraine,buprenorphinemaintenancewasintroduced
in recent years, although coverage remains less than 5% [6].
There is growing concern about emerging epidemics of
HIVamong IDUs in several countries in sub-Saharan Africa
against a backdrop of high HIV prevalence in the general
population. At least in part, the burgeoning number of drug
injectors is believed to be linked to the role that many African
countries now play as trans-shipment routes in the global
trafficking networks for heroin, cocaine, and other drugs [7].
Well-established HIV epidemics among IDUs exist in
Nigeria, Kenya, Tanzania, South Africa, and Mauritius [1•].
For example, by 2008, injecting drug use accounted for 7%
of incident HIV infections in Kenya [8], where the estimated
HIV prevalence among IDUs is already 42% [1•]. In Dar E
Salaam, Tanzania, where HIV prevalence among IDUs is
also 42% [9], local practices such as “flashblood” (i.e.,
deliberately sharing of blood with drug preparations) may be
fueling HIV transmission, but the extent to which this or
similar practices exist elsewhere is unknown. Anecdotal
evidence suggests that prisons may serve to potentiate HIV
transmission due to the ample supply of drugs in the absence
of sterile syringes [7]. To date, opioid substitution therapy
(OST) has been implemented in only a few countries in sub-
Saharan Africa, such as Mauritius, and some countries (e.g.,
Kenya) maintain laws prohibiting its use [10]. In addition,
the high level of re-use of needles in medical establishments
could potentiate HIV transmission, contributing further to
generalized HIV epidemics [7].
Available data suggest that there may be 1,778,500 IDUs
in sub-Saharan Africa (range: 534,500–3,022,500), among
whom an estimated 221,000 (range: 26,000–572,000) may
be HIV-positive [1•]. However, since only 13 of 47
countries in sub-Saharan Africa have collected data on
injecting drug use in their respective countries [1•], it is
possible that injecting drug use, and the number of HIV
infections among injectors, is even more widespread. The
prevalence of drug injection across Africa is now estimated
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Fig. 1 Number and proportion of HIV infection among injecting drug
users (IDUs) by the three leading countries for injecting drug use
100 Curr HIV/AIDS Rep (2010) 7:99–106at 0.2% in the general population, a figure that is
comparable to the United States [7].
Features of the HIV Epidemic Among IDUs
in the United States: Ethnic Disparities
Since the late 1980s, HIV incidence has declined by 80%
among IDUs in the United States [11]. However, injecting
drug use continues to account for a substantial proportion
of new HIV diagnoses, especially considering the indirect
role injecting drug use plays in heterosexual HIV transmis-
sion [12]. In 2007, injecting drug use was the third most
frequently reported risk factor for HIV infection, after male-
to-male sexual contact and high-risk heterosexual contact
[12]. The most striking feature of the HIV epidemic among
IDUs in the United States are the dramatic racial disparities.
During 2004–2007, a total of 152,917 people were
diagnosed with HIV infection in 34 US states, including
19,687 IDUs (12.9%) [12]. The majority of HIV-infected
IDUs were male (62.2%) and aged 35–44 years (33.2%).
Blacks accounted for 57.5% of HIV-infected IDUs, whites
for 21.4%, Hispanics for 19.1%, American Indians or
Alaska Natives for 0.6%, Asians for 0.4%, and Native
Hawaiians or Other Pacific Islanders for 0.1% [12].
The average annual rate of new HIV infection diagnosis
per 100,000 general population during 2004–2007 was 11.0
for black IDUs, 4.9 per 100,000 for Hispanic IDUs, and 0.9
per 100,000 for white IDUs. Among these IDU subgroups,
male blacks had the highest average annual rate of new
HIV diagnosis per 100,000 general population (17.3),
followed by female blacks (9.3), male Hispanics (7.0),
and female Hispanics (2.7) [13].
Among male IDU HIV cases, whites and American
Indian/Alaska natives had a higher proportion of HIV cases
occurring among MSM-IDUs. Among American Indian
communities, having a gay/bisexual identity is referred to
as being “two-spirited.” Among females, the distribution of
injecting drug use related HIV/AIDS diagnoses was similar
across whites, blacks, and Hispanics, but the proportion of
HIV cases attributable to injecting drug use was lower
among Asian/Pacific Islanders and higher among American
Indians [13].
Important changes may be occurring in the epidemio-
logic landscape of HIV infection among IDUs in the United
States, an epidemic that has up until now been so
entrenched among communities of color. In a multicity
study across the United States, Broz and Ouellet [14•]
found a tendency for young black drug users to avoid
injecting drug use in recent years, whereas there was no
such trend among young whites. These data are supported
by race-specific and age-specific trends in HIV cases
collected by the US Centers for Disease Control and
Prevention (Fig. 2). While the proportion of injecting drug
use related HIV cases among whites surpassed blacks in the
20–24 age group and decreased with age [12], the proportion
of injecting drug use related HIV cases among blacks
generally increased with increasing age, and the proportion
of IDU-related HIV cases among Hispanics was similar
forallagegroups[12]. Finally, among 13,519 IDUs recruited
through respondent-driven sampling in a behavioral surveil-
lance study from 2005 to 2006 in 23 US cities, the highest
prevalence of needle sharing was reported among non-
Hispanic whites (66%), followed by 56% among Hispanics
and blacks [11]. Non-Hispanic whites were also less likely to
have had a recent HIV test or to have been reached by an
HIVintervention, compared with Blacks or Hispanics. Taken
together, these provocative data suggest that the dispropor-
tionate burden of HIV cases among black IDUs could begin
to shift over the next few decades.
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Drug Users
The tendency for researchers and policymakers to focus
attention on HIVamong IDUs has tended to overshadow the
extent to which individuals who use drugs by routes of
administration other than injection (e.g., snorting, smoking)
a r ea f f e c t e db yH I V .H o w e v e r ,t r a n s m i s s i o nf r o mI D U st o
non-IDUs and the general population is a growing concern in
some regions with established injecting drug use related HIV
epidemics [15–17]. In New York City [15], two separate
cross-sectional surveys, at a detoxification and methadone
maintenance treatment program from 2001 to 2004 (n=2,121)
and at a research storefront through respondent-driven
s a m p l i n gi n2 0 0 4( n=448), compared HIV prevalence among
injecting and non-injecting heroin and cocaine users. In both
studies, HIV prevalence was nearly identical: 13% among
current injectors and 12% among non-IDUs from the drug
treatment study, and 15% among IDUs and 17% among non-
IDUs in the respondent-driven sampling storefront study.
InBaltimore,MD,409IDUswerecomparedwith165non-
IDUs, all of whom were aged 15–30 years and initiated use of
cocaine, heroin, or crack within the previous 5 years [18].
Similar HIV prevalence was observed among IDUs and non-
IDUs (4.4% vs 3.6%). Elsewhere, HIV prevalence estimates
are similar for non-IDUs and IDUs across countries,
including Rio Grande do Sul, Brazil (11% vs 13%) [19]
and Tijuana, Mexico (4% vs 4%) (Fig. 3)[ 20, 21].
Non-injecting drug use, or high-risk sexual behaviors
associated with their use, may be an important factor
contributing to HIV infection even among IDU populations.
For example, in Yunnan, China, lifetime injecting and non-
injecting drug use were both independently associated with
HIV infection among female sex workers [22]. Among
female sex workers in Tijuana and Ciudad Juarez, Mexico,
injection of cocaine and snorting/smoking methamphet-
amine were both associated with HIV infection [23].
What are the possible mechanisms that explain higher
HIV prevalence among non-IDUs compared to the general
population in some settings? One of the most obvious
explanations is a high degree of mixing or “bridging”
between IDU and non-IDU populations, which can transmit
HIV and other sexually transmitted infections through
overlapping social and sexual networks. A clear example
of this was reported in Manipur, India, where high HIV
prevalence was observed among the wives of IDUs [16].
Similarly, bridging between IDUs and non-IDUs is hypoth-
esized to explain diffusion and “interiorization” of HIV in
Brazil [17]. Bridging of HIV between IDU and non-IDU
populations can be expected to occur in outbreak situations
where there is high HIV-1 viral load and even limited
exposures can cause infection. Since there tends to be
greater overlap between women’s sexual and drug using
networks compared to men’s[ 24], and because male-to-
female HIV transmission is more efficient than female-to-
male transmission, heterosexual females may be more
likely to acquire HIV from their IDU sex partners than
males. Unfortunately, this proportion remains unknown
since HIV transmission categories do not capture the role of
drug use apart from injection.
While sexual transmission bridges between IDUs and
non-IDUs may help explain high HIV prevalence in some
non-IDU populations, a second potential explanation for
higher than average HIV prevalence among some non-IDU
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IDUs may represent true risk factors for HIV infection. In
support of this argument, sharing of non-injection drug
paraphernalia (i.e., straws, dollar bills used for snorting
cocaine, inhalers, and pipes used to smoke crack) has been
established as a risk factor for hepatitis C virus infection
[25, 26], with the explanation being that drug users often
have sores and cracks on their noses/mouths, which could
facilitate viral transmission [26, 27]. While these practices
have been associated with HIV infection in some studies, an
independent association between non-injecting drug use
practices and HIV infection has yet to be reported after
appropriate adjusting for injecting drug use and other
known confounders. Additional studies are needed to
disentangle these behaviors, perhaps using a combination
of techniques such as molecular virology and social
network analysis.
A third explanation for high HIV prevalence among non-
IDU populations may be high levels of unprotected sex
among non-IDUs, as is found among users of stimulants
(i.e., crack, cocaine, methamphetamine). In contrast to
persons who are dependent on heroin, stimulant users often
engage in frequent high-risk behaviors with multiple sex
partners. Context and circumstances vary, but the relation-
ship between crack cocaine and the sex trade is well
established [27–29], with some users trading sex for crack,
rather than money, out of a desperate need to quell their
withdrawal. Crack cocaine is now believed to be a major
contributor to local HIVepidemics in Brazil and parts of the
Caribbean (e.g., Bahamas, Puerto Rico, Dominican Repub-
lic, and Jamaica) [30]. Sex workers who are dependent on
drugs may be less able to negotiate condom use due to
inebriation, impaired judgment, or withdrawal, which may
lead them to acquiesce to offers of unprotected sex for
higher pay [31, 32].
The growing use of methamphetamine and amphetamine-
like stimulants may also play a role in HIVepidemics among
non-IDU populations in various international settings. In a
recent review [33], amphetamine or methamphetamine
was documented in 110 countries, of which over half (n=
60) reported the occurrence of methamphetamine injec-
t i o n .I n j e c t i o no fm e t h / a m p h e t a m i n ea l s oa p p e a r e dt ob e
more common in countries reporting the crystalline form
of the drug, which indicates the need for researchers to
record drug formulation, as well as drug type. There was
some evidence to suggest that its use was more prevalent
in east and southeast Asia, North America, South Africa,
New Zealand, Australia, and a number of European
countries [33].
Certain populations of drug users appear to be higher
consumers of methamphetamine, in particular, members of
the gay/bisexual community who began using it as a party
or “circuit club” drug in the 1990s. Methamphetamine use
among MSM (including gay, bisexual, male-to-female
transsexuals, and non-identifying MSM) in the United
States, Australia, and western Europe ranges from 13% to
39% [34, 35]. MSM who use methamphetamine often
engage in high-risk behaviors such as high levels of
unprotected sex, “marathon” sex, sex trading, and polydrug
use, which includes both coadministration of other drugs at
the same episode, and use of other drugs in different
circumstances [36–38]. HIV incidence rates are double or
triple for MSM who use amphetamines compared to non-
drug using MSM, and may even be higher among MSM
who inject methamphetamine and/or other drugs. A recent
review found strong evidence that methamphetamine was
causally associated with HIV infection, although there is
insufficient evidence to conclude whether the causal
pathway is direct, indirect, or both [38]. Methamphetamine
use may also promote transmission of multidrug-resistant
HIV [39, 40].
Implications for Interventions
The important role of injecting drug use in several regional
HIV epidemics, and the tendency for HIV incidence to
escalate rapidly once prevalence reaches a critical thresh-
old, generally believed to be 5% [41], underscores the need
for rapid, simultaneous scale-up of effective interventions.
It has been well established for at least a decade that NEPs
can significantly reduce HIV prevalence and incidence
among IDUs without incurring negative consequences in
the community, and that OST can reduce the frequency of
injecting drug use to such an extent that it can have a major
impact in reducing HIV incidence at the community level
[42, 43]. Indeed, methadone and buprenorphine mainte-
nance are included on the World Health Organization’s
Essential Drug List. Yet of the 148 countries where
injecting drug use is known to occur, only 82 (55%) were
implementing NEPs and 70 (47%) were implementing
OST; both interventions are available in less than half (66
countries, or 44%) [6]. OST is virtually absent in sub-
Saharan Africa, with the exception of Mauritius, which
introduced it recently.
The fact that less than one third of IDUs in the US
Centers for Disease Control and Prevention’s national
behavioral surveillance program had been reached by an
HIV intervention, and only 73% had ever been tested for
hepatitis C virus [11], underscores the pressing need for
programs that reach those at highest risk of infection, even
in a resource-rich country such as the United States. Given
that the US Congressional ban on federal funding for NEPs
has finally been rescinded after more than two decades of
moral opposition against these programs, it is fervently
hoped that there will be a vigorous revitalization of publicly
Curr HIV/AIDS Rep (2010) 7:99–106 103funded NEPs. Failure to do so will continue to undermine
HIV prevention efforts at a national and international level,
since some countries have delayed implementation of NEPs
on the basis that the United States has been similarly
delinquent. Empirical research has shown that NEPs are not
only invaluable as a source of sterile syringes for disen-
franchised drug injectors, but they are also important
venues for offering ancillary services such as condom
provision, drug treatment referrals, overdose prevention,
HIV/sexually transmitted infection testing and counseling,
tuberculosis screening and treatment, and hepatitis B virus
vaccination [42, 44]. Similarly, there is a parallel need for
low-cost OST given that less than one fifth of drug users in
the United States are receiving drug treatment at any given
time [43].
In countries where HIV infection is already established,
prevention programs need to extend beyond those that
focus on injection and sexual risks, to ensure that when
risky behaviors occur, the likelihood of HIV transmission is
reduced. A recent study of IDUs in Vancouver, Canada
suggests that appropriate coverage of HIV antiretroviral
therapy (ART) at the community level can reduce HIV-1
viral load, and hence the risk of HIV infection [45]. Since it
has also been shown that HIV-positive IDUs are just as
likely to adhere to ART as non-IDUs [46], scaling up ART
coverage should be considered a critical element of a
comprehensive prevention package that includes wide-
spread access to HIV testing and counseling, NEPs, and
OST. A recent review of the international literature
demonstrated that OST was significantly associated with
greater ART adherence among IDUs, providing support for
the integration of drug treatment and HIV treatment for
drug-using populations [47]. There is a dire need to extend
prevention programs to incarcerated populations, where
high-risk injection and sexual behaviors are known to
occur; to date, very few countries extend NEPs, OST, and
ART to prisoners. Since several countries have shown that
safer injection facilities are effective in reducing harms
and encouraging IDUs to enter detoxification and OST
[48], these programs are increasingly being recognized as
an intervention worth including in the HIV prevention
arsenal.
In regions where non-injecting drug use predominates as
a risk factor for HIV infection, behavioral surveillance
should be regularly conducted to monitor rates of transition
from non-injecting to injecting drug use to enable the
implementation of timely interventions. Since trends in
drug use patterns are influenced by macro-level changes in
drug trafficking routes, as well as drug availability, purity,
price, and formulation, efforts to track changes in the global
and regional drug markets may be helpful in forecasting
their impact on local HIV epidemic trajectories. While
prevention programs are clearly needed to prevent tran-
sitions from non-injecting to injecting drug use, behavioral
interventions are also needed to promote safer sex negoti-
ation within the context of ongoing drug use. To date, a few
theory-based interventions based on motivational interview-
ing have shown promise among HIV-positive MSM and
HIV-negative heterosexuals who use methamphetamine
[49, 50]. Finally, safer inhalation rooms should be formally
examined as an HIV prevention intervention for individuals
who smoke or snort drugs such as crack cocaine, heroin,
and methamphetamine, and have been implemented in a
few European countries (e.g., Germany, Holland, Switzer-
land, and Spain). While these approaches may be contro-
versial in some settings, empirically based scientific
evidence—rather than the moral majority—should dictate
which interventions are implemented as a prevention
priority.
Conclusions
IDUs continue to bear a substantial burden of HIV
globally, with high prevalence estimates in Eastern Europe,
North Africa, the Middle East, North America, and many
parts of Asia. In the United States, racial and ethnic
disparities among IDUs are striking, with higher HIV
incidence rates occurring among blacks and Hispanics
compared to whites. Although significant attention has
been given to describing the epidemiology of HIV among
IDUs, the burden of HIV among non-IDUs is of growing
importance due to their high-risk behaviors and over-
lapping social and sexual networks with IDUs. Efforts are
needed to expand coverage of core interventions and to
overcome moral opposition that has hampered the imple-
mentation of some interventions in regions that bear a
disproportionate burden of HIV infections among drug-
using populations.
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